Clinical Investigation Using MED3000 Gel or Tadalafil Tablets in the Treatment of Erectile Dysfunction

NCT ID: NCT04984993

Last Updated: 2023-09-21

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

116 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-09-14

Study Completion Date

2022-07-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

An open-label investigation using MED3000 gel or tadalafil (5 mg) tablets in the treatment of erectile dysfunction in patients from 22 to 70 years of age. Each patients will be expected to participate for up to 30 weeks. Eligible patients will be randomised to receive either MED3000 gel or tadalafil (5 mg) tablets in a 1:1 ratio.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Erectile Dysfunction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Patients will be randomised to receive either MED3000 gel or tadalafil (5 mg) tablets after a 4 -6 week screening period
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

MED3000

MED3000 gel formulation topically applied to the glans penis

Group Type EXPERIMENTAL

MED3000 (Male)

Intervention Type DEVICE

Gel formulation

MED3000 (Female)

Intervention Type DEVICE

Gel formulation

Tadalafil

Tadalafil (5 mg) tablets to be taken orally

Group Type EXPERIMENTAL

Tadalafil 5mg (Male)

Intervention Type DRUG

Tablets

Tadalafil 5mg (Female)

Intervention Type DRUG

Tablets

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MED3000 (Male)

Gel formulation

Intervention Type DEVICE

Tadalafil 5mg (Male)

Tablets

Intervention Type DRUG

MED3000 (Female)

Gel formulation

Intervention Type DEVICE

Tadalafil 5mg (Female)

Tablets

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male heterosexual patients aged 22-70 years.
* Confirmed clinical diagnosis of mild, moderate or severe ED for more than 3 months.
* Involved in a continuous heterosexual relationship with their partner for at least 6 months.

Exclusion Criteria

* Any significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, haematological, endocrinological, metabolic, neurological or psychiatric disease.
* History of unstable medical or psychiatric condition or using any medication that, in the opinion of the Principal Investigator, is likely to affect the patient's ability to complete the investigation or precludes the patient's participation in the investigation.
Minimum Eligible Age

22 Years

Maximum Eligible Age

70 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Futura Medical Developments Ltd.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Arthur Burnett, MD

Role: PRINCIPAL_INVESTIGATOR

Johns Hopkins University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Johns Hopkins University

Baltimore, Maryland, United States

Site Status

Medical Center "Asklepii"OOD

Dupnitsa, , Bulgaria

Site Status

ЕТ "Аssoc. Prof. Stefan Popov - Individual Practice for Specialized Outhospital medical care for Neurology and Pscyhiatry"

Plovdiv, , Bulgaria

Site Status

UMHAT Plovdiv AD

Plovdiv, , Bulgaria

Site Status

MHAT "Silistra"AD

Silistra, , Bulgaria

Site Status

Medical Center "INTERMEDICA"ООD

Sofia, , Bulgaria

Site Status

LTD Health

Batumi, , Georgia

Site Status

Jsc "Evex Clinics"

Kutaisi, , Georgia

Site Status

Rustavi N2 Medical Diagnostic Center

Rustavi, , Georgia

Site Status

Clinic "GIDMEDI"

Tbilisi, , Georgia

Site Status

JSC "Evex clinics"

Tbilisi, , Georgia

Site Status

Raymann LLC

Tbilisi, , Georgia

Site Status

The Mikolowska Medical Center

Katowice, , Poland

Site Status

Provita Sp. z o.o.

Katowice, , Poland

Site Status

Medistica Osteomed

Krakow, , Poland

Site Status

PROVITA Specialised Gynecology and Sexology Practice

Lublin, , Poland

Site Status

Sexology and Pathology of Intercourse Clinic

Warsaw, , Poland

Site Status

Ryszard Smoliński's Medical Cabinet

Wroclaw, , Poland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Bulgaria Georgia Poland

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

FM71

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Study in Erectile Dysfunction
NCT00833638 COMPLETED PHASE4
A Study in Erectile Dysfunction
NCT01130532 COMPLETED PHASE4
Treatment of Erectile Dysfunction II
NCT01037218 COMPLETED PHASE3